RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by James Lillard and Shailesh Singh.
Connection Strength

4.945
  1. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009 Nov 15; 125(10):2288-95.
    View in: PubMed
    Score: 0.371
  2. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009 Sep 28; 283(1):29-35.
    View in: PubMed
    Score: 0.357
  3. Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. Mol Cancer Ther. 2009 Jan; 8(1):178-84.
    View in: PubMed
    Score: 0.349
  4. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004 Dec 15; 10(24):8743-50.
    View in: PubMed
    Score: 0.264
  5. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004 Dec; 84(12):1666-76.
    View in: PubMed
    Score: 0.263
  6. Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Lett. 2019 07 10; 454:1-13.
    View in: PubMed
    Score: 0.178
  7. Mir H, Kaur G, Kapur N, Bae S, Lillard JW, Singh S. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Sci Rep. 2019 02 21; 9(1):2527.
    View in: PubMed
    Score: 0.176
  8. Kapur N, Mir H, Clark Iii CE, Krishnamurti U, Beech DJ, Lillard JW, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016 06 14; 114(12):1343-51.
    View in: PubMed
    Score: 0.145
  9. Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and av?3 integrin clustering. Oncotarget. 2016 Feb 09; 7(6):7343-53.
    View in: PubMed
    Score: 0.143
  10. Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016; 15(6):819-26.
    View in: PubMed
    Score: 0.142
  11. Mir H, Singh R, Kloecker GH, Lillard JW, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015 Apr 30; 6(12):9985-98.
    View in: PubMed
    Score: 0.135
  12. Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014 Oct 30; 5(20):10170-9.
    View in: PubMed
    Score: 0.131
  13. Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Int J Oncol. 2014 Dec; 45(6):2232-40.
    View in: PubMed
    Score: 0.130
  14. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014 Apr; 141(4):514-30.
    View in: PubMed
    Score: 0.126
  15. El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Mol Cancer. 2013 Jun 18; 12:64.
    View in: PubMed
    Score: 0.119
  16. El-Haibi CP, Singh R, Gupta P, Sharma PK, Greenleaf KN, Singh S, Lillard JW. Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. J Proteomics Bioinform. 2012; 5(8):177-184.
    View in: PubMed
    Score: 0.108
  17. Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine. 2012 Feb 01; 30(6):1181-90.
    View in: PubMed
    Score: 0.107
  18. Singh R, Lillard JW, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 2011 06 01; 3(4):1569-82.
    View in: PubMed
    Score: 0.103
  19. Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug; 39(2):373-81.
    View in: PubMed
    Score: 0.103
  20. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.
    View in: PubMed
    Score: 0.103
  21. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011 May; 38(5):1279-85.
    View in: PubMed
    Score: 0.101
  22. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22; 8:62.
    View in: PubMed
    Score: 0.097
  23. Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW, Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res. 2010 Jun 17; 3:15.
    View in: PubMed
    Score: 0.097
  24. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010 Apr 22; 9:85.
    View in: PubMed
    Score: 0.096
  25. Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One. 2010 Feb 25; 5(2):e9432.
    View in: PubMed
    Score: 0.095
  26. Sakthivel SK, Singh UP, Singh S, Taub DD, Novakovic KR, Lillard JW. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines. 2008 Oct 28; 6:6.
    View in: PubMed
    Score: 0.086
  27. Sakthivel SK, Singh UP, Singh S, Taub DD, Igietseme JU, Lillard JW. CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 2008 Aug 13; 8:136.
    View in: PubMed
    Score: 0.085
  28. Singh R, Singh S, Lillard JW. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci. 2008 Jul; 97(7):2497-523.
    View in: PubMed
    Score: 0.084
  29. Singh UP, Singh R, Singh S, Karls RK, Quinn FD, Taub DD, Lillard JW. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 2008 Jun 04; 9:25.
    View in: PubMed
    Score: 0.084
  30. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008 Jan; 28(1):31-43.
    View in: PubMed
    Score: 0.081
  31. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007 Aug; 75(8):3722-8.
    View in: PubMed
    Score: 0.078
  32. Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W, Sampson JS, Stiles JK, Taub DD, Lillard JW. CCL5 modulates pneumococcal immunity and carriage. J Immunol. 2006 Feb 15; 176(4):2346-56.
    View in: PubMed
    Score: 0.072
  33. Palaniappan R, Singh S, Singh UP, Sakthivel SK, Ades EW, Briles DE, Hollingshead SK, Paton JC, Sampson JS, Lillard JW. Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun. 2005 Feb; 73(2):1006-13.
    View in: PubMed
    Score: 0.067
  34. Singh UP, Singh S, Ravichandran P, Taub DD, Lillard JW. Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts. J Immunol. 2004 Nov 01; 173(9):5509-16.
    View in: PubMed
    Score: 0.065
  35. Singh UP, Singh S, Boyaka PN, McGhee JR, Lillard JW. Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rbeta interactions. J Leukoc Biol. 2004 Dec; 76(6):1240-7.
    View in: PubMed
    Score: 0.065
  36. Singh UP, Singh S, Iqbal N, Weaver CT, McGhee JR, Lillard JW. IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res. 2003 Oct; 23(10):591-600.
    View in: PubMed
    Score: 0.061
  37. Singh UP, Singh S, Taub DD, Lillard JW. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol. 2003 Aug 01; 171(3):1401-6.
    View in: PubMed
    Score: 0.060
  38. Sarfo BY, Armah HB, Irune I, Adjei AA, Olver CS, Singh S, Lillard JW, Stiles JK. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malar J. 2005 Dec 16; 4:63.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support